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Background: This study evaluated the efficacy and safety of S-1 combined with docetaxel (SD) following doxorubicin
plus cyclophosphamide (AC) as neoadjuvant therapy in patients with HER2-negative, stage II-III breast cancer.
Methods: Patients received AC every 3 weeks for four cycles followed by S-1 (30 mg/m2 orally b.i.d. on days 1–14) and
docetaxel (75 mg/m2 i.v. on day 1) every 3 weeks for four cycles. The primary endpoint was the pathological complete
response (pCR) rate in breast and axillary lymph nodes.
Results: The study included 49 patients with a median age of 43 years. The median breast tumor size was 4.0 cm by
palpation. All patients were positive for involvement of axillary lymph node and five patients also had supraclavicular
lymph node metastasis, which was confirmed by histological examination. In total, 85.4% of patients (41/49) completed
eight cycles of therapy and 95.9% of patients (47/49) received curative surgery. The pCR rate was 22.5% (n = 11). The
clinical response rate was 67.4%. During SD chemotherapy, the most frequent grade 3–4 toxicity was neutropenia
(8.5% by cycle). There was a single treatment-related mortality from severe neutropenia. Grade 3 S-1 specific toxicities
such as epigastric pain (12.2% by person), stomatitis (4.1% by person), and diarrhea (2.0% by person) were also
observed. In particular, gastrointestinal discomfort led to dose reduction of S-1 in 45.8% of patients.
Conclusions: Given all axillary lymph node positive diseases, neoadjuvant S-1 combined with docetaxel following AC
showed a favorable anti-tumor activity but gastrointestinal discomfort should be carefully considered for future studies.
Trial registration: NCT00994968
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Neoadjuvant (pre-operative) chemotherapy is the standard
of care in patients with inoperable locally advanced breast
cancer, and is increasingly being considered for patients
with operable disease [1]. Between pre- and postoperative
chemotherapy, comparable clinical outcomes have been
found, but in most studies breast-conserving surgery
(BCS) was possible more often after preoperative treat-
ment [2]. Combined doxorubicin and cyclophosphamide
(AC) and sequential docetaxel is a widely accepted* Correspondence: oncosohn@yuhs.ac
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reproduction in any medium, provided the orregimen for neoadjuvant chemotherapy based on the Na-
tional Surgical Adjuvant Breast and Bowel Project Proto-
cols (NSABPs) B-27 study, which demonstrated that
sequential addition of docetaxel increased the rate of
pathological complete response (pCR) compared with AC
alone [3]. The pCR is known to be a short-term surrogate
marker of neoadjuvant chemotherapy that strongly corre-
lates with long-term clinical outcome [4]. Accordingly,
one of the strategies to improve pCR is to add new com-
pounds to established treatments.
S-1 is an orally bioavailable fluoropyrimidine antagonist
composed of tegafur, a prodrug of 5-flurouracil (5-FU),
combined with two modulators of 5-FU activity, 5-chloro-
2,4-dihydroxypyridine (CDHP) and potassium oxonate.
CDHP potentiates the effect of 5-FU by blocking the rapidtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nate preferentially localizes in the gut where it inhibits local
activation of 5-FU, thereby decreasing 5-FU-related gastro-
intestinal toxicity [5]. Clinically, S-1 has been widely ap-
proved for gastric cancer treatment in many countries in
Asia and Europe [6] and for several other cancers in Japan
[7]. In a phase 2 clinical trial (n = 111), S-1 monotherapy
showed activity and tolerability in metastatic breast cancer
with a response rate of 42%, warranting further research on
the role of S-1 in breast cancer [8].
A S-1 plus docetaxel combination was reported to
have a synergistic antitumor effect in a breast cancer
xenograft study, suggesting partly through significant
down-regulation of the activity of dihydropyrimidine de-
hydrogenase, the rate-limiting enzyme in the catabolism
of 5-FU [9]. However, the mechanism underlying the syn-
ergism of these compounds is not fully understood. Al-
though a S-1 and docetaxel combination was active and
tolerable in several phase II trials of gastric cancer [10]
and non-small cell lung cancer patients [11], a clinical
study of this combination therapy in breast cancer patients
has not been published to date.
Based on these results, the present phase II trial was de-
signed to evaluate the efficacy and the safety of a combi-
nation of S-1 and docetaxel following AC chemotherapy
as neoadjuvant treatment in stage II-III breast cancer.Methods
Patient eligibility
Women with previously untreated clinical stage II or III
breast cancer were eligible for this neoadjuvant trial if
the following eligibility criteria were met: i) pathologic-
ally confirmed invasive ductal or lobular carcinoma
from a core biopsy specimen; ii) HER2-negativity of 0 or
1+ by immunohistochemistry, or HER2 non-amplification
by fluorescent in situ hybridization; iii) age ≥18 years; iv)
Eastern Oncology Cooperative Group performance status
of ≤1; v) adequate cardiac function (left ventricular ejec-
tion fraction > 50%); vi) adequate bone marrow (neutro-
phils ≥1.5 × 103/μl, platelets ≥100 × 103/μl, Hb ≥10.0 g/dl),
renal function (serum creatinine ≤1.5 times the upper nor-
mal limit or creatinine clearance ≥ 50 ml/min by Cockroft
formula), and liver function (serum bilirubin ≤1.5 times the
upper normal limit, aspartate aminotransferase/alanine ami-
notransferase ≤2.5 times the upper normal limit) within
2 weeks before starting the therapy; and vii) no previous
chemo-, radio- or hormone therapy. Patients were excluded
if they met the following criteria: i) T4d/inflammatory breast
cancer; ii) potentially or currently pregnant or lactating; iii)
taking medications that alter the pharmacokinetics of S-1
(for example, allopurinol, phenytoin); or iv) inability to swal-
low S-1 tablets or malabsorptive gastrointestinal condition.All patients provided written informed consent and
this study was approved by the Institutional Review
Board of Severance Hospital, Seoul, Korea.Study treatment
This was a single-arm, single-center, phase II study of S-1
combined with docetaxel (SD) following doxorubicin plus
cyclophosphamide (AC) as neoadjuvant chemotherapy in
patients with stage II-III breast cancer. Neoadjuvant
chemotherapy schedule was as follows: For the initial AC
treatment, doxorubicin (60 mg/m2 i.v. on day 1) and
cyclophosphamide (600 mg/m2 i.v. on day 1) were admi-
nistered every 3 weeks for four cycles. Upon completion
of AC treatment, if the diseases had not progressed by
physical and radiological examinations and toxicities were
acceptable, SD treatment with S-1 (30 mg/m2 orally b.i.d.
on days 1–14) and docetaxel (75 mg/m2 i.v. day 1) was
given every 3 weeks for four cycles.
Modifications of doses and dosing schedules were as
follows: If the neutrophil count was ≥1.5 × 103/μl and
the platelet count was ≥100 × 103/μl, we would begin
the next cycle for both AC and SD. If these values were
not reached, AC or SD was delayed by 1 week. At the end
of the first week of delay, if the neutrophil count was 1.0–
1.5 × 103/μl and the platelet count was 75–100 × 103/μl,
the next doses of doxorubicin/cyclophosphamide and
S-1/docetaxel were reduced by 1 step to 50/500 mg/m2
and 25/60 mg/m2, respectively. If the neutrophil count
was ≤1.0 × 103/μl or the platelet count was ≤75 × 103/μl,
therapy was delayed for one more week. After the second
week of delay, if the neutrophil count was ≥1.5 × 103/μl
and the platelet count was ≥100 × 103/μl, AC and SD were
reduced by 1 step; however, if these values were not
reached, the trial would be stopped. Granulocyte colony-
stimulating factor (G-CSF) was administered in the case
of febrile neutropenia. Prophylactic G-CSF usage was
permitted from the second cycle. Regarding non-
hematological toxicity, if grade 3–4 S-1 specific toxicities
such as diarrhea, stomatitis, or epigastric pain were ob-
served, S-1 was omitted and restarted at a 1-step lower
dose when toxicities were recovered to grade 1 or baseline;
however, docetaxel administration was continued. If grade
3–4 peripheral neuropathy was observed, docetaxel was
omitted and restarted at a 1-step lower dose when toxicities
recovered to grade 1 or baseline. If grade 3–4 abnormalities
of serum bilirubin, alkaline phosphatase, aspartate amino-
transferase, or alanine aminotransferase increase were ob-
served, docetaxel and S-1 were delayed and restarted at a
1-step lower dose when toxicities recovered to grade 1 or
baseline. If the other grade 3–4 non-hematological toxi-
cities were observed, AC or SD could be delayed and re-
duced according to the investigator’s discretion.
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The type of breast surgery after neoadjuvant chemothe-
rapy was determined by using a multidisciplinary team ap-
proach considering the clinical and radiological response
to neoadjuvant chemotherapy, presence of multifocal or
multicentric tumor, and patient preference. All patients
with initial axillary node-positive disease underwent stand-
ard level I/II axillary lymph node dissection with or with-
out explorative sentinel lymph node biopsy. Patients with
Initially cytology-proven supraclavicular lymph node me-
tastasis underwent supraclavicular lymph node dissection.
After surgery, all patients received adjuvant radiotherapy
covering the whole breast and regional nodes including
supraclavicular area. Patients with hormone receptor-
positive tumors received adjuvant endocrine therapy.
However, postoperative adjuvant chemotherapy was not
scheduled. If tumors were not resectable, patients were
taken off the clinical trial.
Study endpoints
The primary endpoint was the pCR rate, defined as
the absence of invasive carcinoma in the breast and no
involvement of carcinoma to axillary nodes (AXLNs)
(i.e., pathological stage T0N0 or TisN0). Secondary
endpoints were the clinical response rate, safety, pCR
rate in the breast regardless of AXLN, and BCS rate.
Assessments of endpoints
Tumor measurement by mammography, ultrasonography,
and/or MRI was scheduled at baseline, at the completion
of four cycles of AC, and before surgery. The breast and
regional lymph nodes were examined by palpation every
cycle. A PET-CT scan was performed at baseline and at
the completion of chemotherapy to exclude distant metas-
tases. Pathological responses of the breast tumor and infil-
tration of regional lymph nodes were assessed and staged
according to the TNM system. The clinical response was
defined according to the Response Evaluation Criteria for
Solid Tumors (version 1.1) [12]. Toxicity was graded based
on the National Cancer Institute’s Common Terminology
Criteria for Adverse Events version 3.0. For pathological
assessment, excised tissues from the breast were cut to
5-mm thickness and those from the regional lymph
nodes to 2-mm thickness. Patients were considered to
have had BCS if the final surgical procedure was tumo-
rectomy, segmentectomy, or quadrantectomy.
Statistical analysis
The null hypothesis is that the pCR rate is 11%. This
pCR rate was estimated lower than 14.3% obtained by
docetaxel following by AC in GEPARDUO study in
which only operable T2-3 and N0-2 tumors were en-
rolled but our study enrolled more advanced stages with
pathologically confirmed axillary node involvement (T1-4c and N1-3) including inoperable, stage III tumors [13].
The alternative hypothesis is that addition of S-1 in
combination with docetaxel will increase the pCR rate to
25%. With a two-sided significance level of 0.05 and a
power of 0.8 to reject the null hypothesis, the minimum
sample size was determined to be 44. Assuming a 10%
of drop-out rate, the final sample size was calculated to
be 49 patients. An optimal cut-off point for Ki67 was de-
termined as 30% using the minimum P value approach
in the analysis of predictors of pCR.
Results
Patient characteristics
From July 2009 to September 2011, 49 patients were en-
rolled in this study at Severance Hospital, Yonsei University
Health System, Seoul, Korea. All 49 patients received at
least one dose of study treatment and were included in the
evaluation of pCR and toxicity [intention to treat (ITT)
population]. Baseline characteristics of the 49 patients are
summarized in Table 1. All patients were positive for in-
volvement of axillary lymph node and five patients also had
supraclavicular lymph node (SCL) metastasis. Involvement
of axillary and supraclavicular node was confirmed by fine
needle aspiration and histological examination.
Overview of treatment results
Forty-one patients (83.7%) completed four cycles of AC
and four cycles of SD chemotherapy and also underwent
surgery. Among eight patients (16.3%) who could not
complete the scheduled chemotherapy, one was lost to
follow-up during AC cycles and seven were taken off
the study during SD cycles for the following reasons:
two withdrew consent after 1 cycle; three exhibited to-
xicity after 1, 2, or 3 cycles; one had disease progression
after 2 cycles; one died from septic shock after 2 cycles.
Six of the seven patients who dropped out during SD
cycles received surgery.
Efficacy outcomes
Efficacy outcomes are summarized in Table 2. The primary
endpoint, the rate of pCR in both breast and AXLN, was
22.5% (n = 11) in the ITT population. The rate of pCR in
the breast and in AXLN was 30.6% (n = 15) and 40.8%
(n = 20), respectively. In the per protocol population,
which excluded patients who were lost to follow-up (n = 1)
or withdrew consent (n = 2), the rate of pCR in the breast
and AXLN was 23.9% (11/46). The rate of BCS was 42.9%
(21/49). The pCR rate in the breast and AXLN was 30.8%
(4/13) for the triple-negative disease and 19.4% (7/36) for
hormone receptor-positive disease.
Clinical response was observed in 67.4% of patients
(6 complete and 27 partial responders among 49 patients).
Fourteen patients (28.6%) showed stable disease and one
patient (2.0%) showed progressive disease. According to
Table 1 Patient characteristics (ITT population)
Characteristics n (%)
Number of total patients 49
Median age, years (range) 43 (27–60)
Menopausal status
Premenopause 42 (85.7%)
Postmenopause 7 (14.3%)
Histology
Invasive ductal carcinoma 46 (93.9%)
Invasive lobular carcinoma 1 (2.0%)
Mixed type (ductal + lobular) 2 (4.1%)
ECOG performance status
0 25 (51.0%)
1 24 (49.0%)
Prechemotherapy T stage
cT1 5 (10.3%)
cT2 37 (75.5%)
cT3 6 (12.2%)
cT4 1 (2.0%)
Prechemotherapy N stage
cN0 0 (0.0%)
cN1 30 (61.2%)
cN2 14 (28.6%)
cN3 5 (10.2%)
AJCC clinical stage
IIA 3 (6.1%)
IIB 25 (51.0%)
IIIA 16 (32.7%)
IIIB 0 (0.0%)
IIIC 5 (10.2%)
Median tumor size by palpation, cm (range) 4.0 (0–11.0)
Hormonal receptor status*
Positive for ER or PgR 36 (73.5%)
Negative for ER and PgR 13 (26.5%)
HER2 status
Positive 0 (0.0%)
Negative 49 (100%)
ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; PgR,
progesterone receptor. *The cut-off of ER and PgR positivity was 10% stained
cells by immunohistochemistry.
Table 2 Summary of efficacy outcomes
ITT population (n = 49)
Endpoints n (%)
pCR* in breast and AXLN 11 (22.5%)
pCR* in breast 15 (30.6%)
Clinical response
Complete response 6 (12.3)
Partial response 27 (55.1)
Stable disease 14 (28.6)
Progressive disease 1 (2.0)
Non-assessable 1 (2.0)
Breast-conserving surgery
Yes 21 (42.9)
No 26 (53.1)
Non-assessable 2 (4.0)
ITT, intent-to-treat; pCR, pathological complete response; *pCR was defined as
the absence of invasive disease.
Table 3 Univariate analysis for predictors of pathologic
complete response
Variables N pCR n
(%)
Non-pCR
n (%)
P
value*
Ki-67 <30% 15 2 (13.3) 13 (86.7) 0.070
≥30% 18 8 (44.4) 10 (55.6)
Initial tumor size ≤2 cm 7 4 (57.1) 3 (42.9) 0.083
>2 cm 32 7 (21.9) 25 (78.1)
Initial clinical
stage
II 22 5 (22.7) 17 (77.3) 0.482
III 17 6 (35.3) 11 (64.7)
Age, year < median
(43)
20 7 (35.0) 13 (65.0) 0.480
≥ median
(43)
19 4 (21.1) 15 (78.9)
HR (10% of cut-
off)
Negative 11 4 (36.4) 7 (63.6) 0.694
Positive 28 7 (25.0) 21 (75.0)
HR, hormone receptor. *Chi-square or Fisher’s exact test.
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67.4% in the breast (7 complete and 26 partial re-
sponders), 55.1% in the AXLN (27 complete responders),
and 40.0% in the SCL (2 complete responders out of
5 with SCL metastasis). Subsequent clinical response to
SD chemotherapy was evaluated in 31 patients who had
serial sonographs. The median tumor size in the breast
was 26 mm, 13 mm, and 10 mm at baseline, completionof AC, and completion of SD chemotherapy, respec-
tively. Compared to tumor size before SD chemother-
apy, subsequent clinical response rates in the breast to
SD chemotherapy were: complete response, 6.9% (2/29);
partial response, 31.0% (9/29); stable disease, 62.1% (18/29).
Two complete responses to AC chemotherapy were main-
tained after subsequent SD chemotherapy.
In an exploratory finding, tumors with high Ki-67
(≥30%) or small initial size of tumor (≤2 cm) showed a
trend toward a higher pCR rate than those without but
they did not reach statistical significance (Table 3).
Table 4 Toxicity profiles of AC/SD chemotherapy
NCI-CTC AE grade
Toxicities G1 G2 G3 G4 G5 ≥G3 (%)
Hematologic toxicity
(by cycle)
Neutropenia 2/1 1/3 6/6 6/9 0/0 12/15 (6.2/8.7)
Febrile neutropenia 0/0 0/0 6/4 0/1 0/0 6/5 (3.1/2.9)
Anemia 0/0 0/0 0/1 2/0 0/0 2/1 (1.0/0.6)
Non-hematologic toxicity
(by patient)
Epigastric pain 7/15 3/2 0/6 0/0 0/0 0/6 (0/12.2)
Nausea 19/11 8/4 1/2 0/0 0/0 1/2(2.0/4.1)
Vomiting 8/9 4/3 1/2 0/0 0/0 1/2 (2.0/4.1)
Stomatitis/mucositis 12/14 2/10 0/2 0/0 0/0 0/2 (0/4.1)
Infection 0/0 1/1 1/0 0/1 0/1 1/2(2.0/4.1)
Increased ALT 0/0 0/2 1/2 0/0 0/0 1/2 (2.0/4.1)
Myalgia 6/13 1/7 0/1 0/0 0/0 0/1 (0/2.0)
Diarrhea 2/4 2/2 0/1 0/0 0/0 0/1 (0/2.0)
Hand-foot syndrome 0/1 0/3 0/1 0/0 0/0 0/1 (0/2.0)
Anorexia 18/10 3/9 0/0 0/0 0/0 0/0 (0/0)
Constipation 9/8 1/7 0/0 0/0 0/0 0/0 (0/0)
Arthralgia 1/2 1/3 0/0 0/0 0/0 0/0 (0/0)
Peripheral neuropathy 2/6 0/3 0/0 0/0 0/0 0/0 (0/0)
Edema 1/9 0/1 0/0 0/0 0/0 0/0 (0/0)
Fatigue 16/0 0/1 0/0 0/0 0/0 0/0 (0/0)
NCI-CTC AE, National Cancer Institute-Common Terminology Criteria for Adverse
Events. Total number of cycles delivered was 193/172 cycles for AC/SD.
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All grades of hematologic (by cycle) and non-hematologic
(by patient) toxicities are listed in Table 4. Toxicities of
AC chemotherapy were mainly grade 1–2 nausea, vomi-
ting and anorexia as expected. In the SD cycles, the dom-
inating grade 3–4 toxicity was myelosuppression and
epigastric pain. Grade 3–4 hematological toxicities were
neutropenia (8.5%) and febrile neutropenia (2.9%). After
two cycles of SD, one neutropenic patient experiencedTable 5 Comparison of neoadjuvant trials with AC followed b
Trials Patients
Tumor cLN+
Stage >4 cm (%)
This study T1-4c, N1-3 45% 100%
NSAPB B-27 [3] T1c-3, N0-1 45% 30%
45% 30%
GEPARDUO [13] T2-3, N0-2 32% 38%
33% 42%
A, doxorubicin; C, cyclophosphamide; CIS, carcinoma in situ; cLN, clinically detected
cates that the definition of pCR includes or does not include CIS.infection that led to death. S-1 specific toxicities were as
follows: epigastric pain, 20.4% at grade 1–2 and 12.2% at
grade 3; stomatitis, 28.6% at grade 1–2 and 4.1% at grade
3; diarrhea, 8.2% at grade 1–2 and 2.0% at grade 3; hand-
foot syndrome, 8.2% at grade 1–2 and 2.0% at grade 3.Treatment delivery and dose intensity
Since AC chemotherapy is a routine treatment and SD
chemotherapy is experimental, dose-intensity analysis fo-
cused on SD chemotherapy. In total, 172 cycles of SD
chemotherapy were delivered. Docetaxel was delayed in
7 cycles (4.1%), mainly due to neutropenia. At least one
dose of S-1 was omitted in 27 cycles (15.7%) due to sto-
matitis (6 cycles), epigastric pain (4 cycles), and other
toxicities (17 cycles). Of 48 patients who received at least
one cycle of SD chemotherapy, 12 patients (25%) re-
quired dose reduction of both docetaxel and S-1 due to
infection (n = 2), neutropenia (n = 2), asthenia (n = 2),
and other toxicities (n = 6). Two patients (4.2%) required
dose reduction in only docetaxel and 10 patients (20.8%)
in only S-1, mainly due to epigastric pain (n = 7). Five of
these 10 patients discontinued S-1 completely after 1 (n =
1), 2 (n = 2), or 3 cycles (n = 2). The mean relative dose in-
tensity (RDI) of docetaxel and S-1 was 91.4% and 79.6%,
respectively.Discussion
The current study evaluated the efficacy and tolerability of
S-1 in combination with docetaxel following AC chemo-
therapy as neoadjuvant treatment in patients with HER2-
negative, stage II-III breast cancer. To the best of our
knowledge, this is the first neoadjuvant trial to test a doce-
taxel plus S-1 combination in breast cancer patients.
Given all patients had pathologically confirmed axillary
lymph node involvements, this novel combination showed
activity with a favorable pCR rate (22.5%) in both breast
and axillary nodes, although the primary endpoint, pCR,
did not reach the predetermined threshold level (25%).
Further, gastrointestinal discomfort should be carefully
considered for future studies. However, concomitanty docetaxel with or without S-1
Regimen pCR
Breast + LN Breast
+CIS* –CIS** +CIS –CIS
AC→SD 22.5% NA 30.6% 22.5%
AC 11.5% NA 13.7% 9.6%
AC→D 21.8% NA 26.1% 18.9%
AD NA 7.0% 11.0% 7.0%
AC→D NA 14.3% 22.3% 15.9%
lymph node; D, docetaxel; NA, non-assessable; S, S-1. ‘* + CIS’ or ‘**–CIS’ indi-
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docetaxel.
Comparing cross-study efficacy of chemotherapy needs
special attention regarding the design of the studies such
as patient population, definition of endpoint, and dose in-
tensity. As shown in Table 5, in the NSABP B-27 study,
AC-D produced a similar pCR rate in the breast and
lymph nodes (21.8%) to our study (22.5%); however, cli-
nical nodal involvement (30%) was less frequent than in
our study (100%). In addition, NSABP B-27 did not enroll
patients with cN2-3, whereas such patients represented
38.8% of our study population. The tumor size was similar
between the two studies. In the GEPARDUO study [13],
which is another phase III neoadjuvant study using AC-D
regimen, the pCR rate in the breast with AC-D (22.3%)
was lower than the pCR rate in our data (30.6%) and both
studies had comparable median tumor size (4 cm). In
terms of dose intensity, docetaxel delivery was scheduled
at a higher dose in the prior two studies (100 mg/m2) than
in our study (75 mg/m2).
Based on reports that capecitabine, which is another pro-
drug of 5-FU, in combination with docetaxel showed su-
perior efficacy over docetaxel monotherapy in patients
with metastatic breast cancer [14], adjuvant and neoadju-
vant trials were conducted with a combination of capecita-
bine and docetaxel. However, combination treatment did
not result in significantly improved pCR rates in the neoad-
juvant GEPARQUATTRO [15] and NSABP B-40 trials
[16]. In the adjuvant FinXX trial [17], integration of cape-
citabine into an adjuvant regimen that contained docetaxel,
epirubicin, and cyclophosphamide did not significantly im-
prove recurrence-free survival compared with a similar
regimen without capecitabine. Exploratory subset analysis
of the neoadjuvant GEPARQUATTRO study showed that
in cT4 tumors (n = 152) a capecitabine plus docetaxel
combination produced a higher pCR rate (18.9%) than doc-
taxel monotherapy (5.1%). In subset analysis of the adju-
vant FinXX trial, in patients with triple-negative disease or
more than three metastatic axillary lymph nodes the
addition of capecitabine improved recurrence-free survival.
Taken together, these results suggest that the efficacy bene-
fit of capecitabine may be limited to patients with a high
risk of breast cancer recurrence when used in neoadjuvant
and adjuvant settings.
In the current study, SD following AC produced a higher
pCR rate in triple-negative disease than in hormone
receptor-positive disease. Considering triple-negative dis-
ease, which is biologically more aggressive, is generally
more chemosensitive to neoadjuvant chemotherapy [18],
we cannot exclude the possibility that our regimen might
be more beneficial in triple-negative disease. Further studies
to incorporate S-1 into docetaxel following AC might be
worthwhile in patients with a relatively high risk of recur-
rence including triple-negative disease.In determining doses of S-1 and docetaxel we did not
want to compromise the dose of docetaxel, which is an
approved active drug in the neoadjuvant setting of breast
cancer. We therefore fixed the dose of docetaxel at
75 mg/m2 in 3 weeks, which is an effective and tolerable
dose in Korean patients [19]. As recommended in a
phase I trial of S-1 and docetaxel conducted in gastric can-
cer [20], we determined the dose of S-1 to be 30 mg/m2
b.i.d. instead of 35 mg/m2 b.i.d. for 14 days every
3 weeks, which is a widely accepted dose for monother-
apy in Korea [21]. At these doses and dosing schedules,
grade 3–4 neutropenia was not frequent (8.5% by cycle)
and was mostly manageable except for a single case of
treatment-related death from severe neutropenia. How-
ever, gastrointestinal discomfort caused by S-1 was a
hurdle to administer S-1 in some patients. It is note-
worthy that 20.8% of patients (n = 10) needed dose re-
duction of S-1, and five of these (10.4% of total
patients) stopped S-1 treatment due to intolerability.
Despite this, the RDI of docetaxel (91%) could be main-
tained at a high level by omitting or reducing only S-1
when S-1 specific toxicities were encountered. The RDI
of S-1 was down to 80% with the strict modification in
dosing of S-1,
Conclusion
In conclusion, given all axillary lymph node positive dis-
eases, S-1 combined with docetaxel following AC showed
a favorable anti-tumor activity, although the primary end-
point was not met. Further, gastrointestinal discomfort
should be carefully considered for future studies.
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